Published in Nat Genet on September 01, 1994
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg (1995) 5.66
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer (2010) 3.27
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol (1995) 3.19
Phenotype and genotype of pancreatic cancer cell lines. Pancreas (2010) 3.06
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol (1995) 2.62
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Biology and management of pancreatic cancer. Gut (2007) 2.53
The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol (1998) 2.53
Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J (1995) 2.26
Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One (2009) 2.21
A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev (2001) 2.05
Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol (2008) 1.87
Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78
Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg (2007) 1.74
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer (2010) 1.66
Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer (1997) 1.65
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A (2000) 1.64
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc Natl Acad Sci U S A (1998) 1.60
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Genetic progression and divergence in pancreatic carcinoma. Am J Pathol (2000) 1.53
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Genome-wide association study of pancreatic cancer in Japanese population. PLoS One (2010) 1.50
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med (2011) 1.46
Retracted Polymorphism of 9p21.3 locus is associated with 5-year survival in high-risk patients with myocardial infarction. PLoS One (2013) 1.45
Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci U S A (1995) 1.44
Genetic alterations in pancreatic carcinoma. Mol Cancer (2003) 1.43
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
The PMAIP1 gene on chromosome 18 is a candidate tumor suppressor gene in human pancreatic cancer. Dig Dis Sci (2008) 1.40
Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res (2012) 1.37
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol (1999) 1.36
Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer (2001) 1.36
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.32
Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol (2004) 1.32
High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol (1996) 1.32
Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem (2010) 1.31
Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (1997) 1.29
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A (2001) 1.29
Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res (2009) 1.28
A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol (2000) 1.26
Bayesian Hidden Markov Modeling of Array CGH Data. J Am Stat Assoc (2008) 1.25
Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One (2009) 1.23
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One (2012) 1.21
Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol (2016) 1.20
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut (2011) 1.20
Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest (1998) 1.19
Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci U S A (1996) 1.14
Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet (1999) 1.13
Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm Res (2008) 1.13
Novel fluorescence in situ hybridization approaches in solid tumors. Characterization of frozen specimens, touch preparations, and cytological preparations. Am J Pathol (1995) 1.13
A novel approach for determining cancer genomic breakpoints in the presence of normal DNA. PLoS One (2007) 1.12
Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol (2013) 1.11
Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg (1999) 1.08
Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br J Cancer (1997) 1.07
Allelotype of 28 human breast cancer cell lines and xenografts. Br J Cancer (2003) 1.06
Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol (1996) 1.06
N-cadherin and keratinocyte growth factor receptor mediate the functional interplay between Ki-RASG12V and p53V143A in promoting pancreatic cell migration, invasion, and tissue architecture disruption. Mol Cell Biol (2006) 1.06
Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br J Cancer (1997) 1.04
Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn (2008) 1.04
Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology (2011) 1.04
Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int (2011) 1.03
Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer (2002) 1.03
Pancreatic cancer screening. Gastroenterol Clin North Am (2012) 1.02
Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. Am J Hum Genet (1995) 1.02
Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis. Cancer Ther (2007) 1.02
Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol (2007) 1.02
Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol (1998) 1.01
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J (2005) 1.00
Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer. FEBS Lett (2012) 0.98
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am J Pathol (2010) 0.98
Effect of 5-Aza-2'-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2. World J Gastroenterol (2001) 0.98
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. BMC Gastroenterol (2005) 0.97
SCF(beta-TrCP1) controls Smad4 protein stability in pancreatic cancer cells. Am J Pathol (2005) 0.96
Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res (2013) 0.96
Basic principles and technologies for deciphering the genetic map of cancer. World J Surg (2009) 0.96
Genomic sequencing of key genes in mouse pancreatic cancer cells. Curr Mol Med (2012) 0.96
Therapeutic options for the management of pancreatic cancer. World J Gastroenterol (2014) 0.96
Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet (1996) 0.96
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer (1995) 0.95
Molecular pathways in pancreatic carcinogenesis. J Surg Oncol (2012) 0.95
Role of Radiation-induced TGF-beta Signaling in Cancer Therapy. Mol Cell Pharmacol (2009) 0.95
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol (1995) 0.95
Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. Gut (2004) 0.94
Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol (1997) 0.93
Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol (2014) 0.91
p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium. EMBO Mol Med (2010) 0.91
Biological approaches to therapy of pancreatic cancer. Pancreatology (2008) 0.91
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci (2013) 0.91
Overexpression of p53 protein during pancreatitis. Br J Cancer (1997) 0.91
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One (2012) 0.90
Ski promotes tumor growth through abrogation of transforming growth factor-beta signaling in pancreatic cancer. Ann Surg (2007) 0.90
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg (1997) 8.86
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg (2001) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med (2000) 6.27
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg (1993) 5.87
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg (1995) 5.66
Allelotype of colorectal carcinomas. Science (1989) 5.54
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg (1998) 4.19
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg (1991) 3.88
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med (2000) 3.70
Scrambled exons. Cell (1991) 3.65
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant (1996) 3.51
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg (1999) 3.09
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res (1998) 2.89
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res (1994) 2.80
Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg (2001) 2.80
The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev (1998) 2.72
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol (2000) 2.63
Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg (1998) 2.60
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Genetic progression in the pancreatic ducts. Am J Pathol (2000) 2.58
Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg (1997) 2.53
Mad-related genes in the human. Nat Genet (1996) 2.51
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50